Prognostic Value of Cycle 1 SPECT SUVmean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617.
Saved in:
| Title: | Prognostic Value of Cycle 1 SPECT SUV |
|---|---|
| Authors: | Ghodsi A; Department of Radiology, University of Washington, Seattle, Washington., Demirci RA; Department of Radiology, University of Washington, Seattle, Washington., Gulati R; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington., Nelson PS; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Raychaudhuri R; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Cheng HH; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and., Sunkara R; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Khan H; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Rios RN; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Hsieh A; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Grivas P; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Montgomery B; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Yezefski TA; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Yu EY; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Schweizer MT; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Chen DL; Department of Radiology, University of Washington, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Iravani A; Department of Radiology, University of Washington, Seattle, Washington; airavani@uw.edu.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2026 Jun 01; Vol. 67 (6), pp. 921-925. Date of Electronic Publication: 2026 Jun 01. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1535-5667 |
|---|---|
| DOI: | 10.2967/jnumed.125.271593 |
